从肺论治降低系统性红斑狼疮感染率的临床研究

Clinical Research on Effect of TCM Treatment Beginning with Fei in Treating Systemic Lupus Erythematosus for Reducing Incidence of Complicated Infection

目的观察从肺论治降低系统性红斑狼疮(SLE)感染率及抗生素使用率的作用。方法将110例SLE患者随机分为治疗组(55例)和对照组(55例),两组西医治疗方案相同。治疗组同时加用中药,病情活动期和静止期分别使用狼疮Ⅰ号及Ⅱ号协定方,对照组单纯使用西药治疗。结果总有效率比较治疗组治疗3个月和6个月后分别为83．64％(46／55例)、87．27％(48／55例),对照组分别为78．18％(43／55例)、81．82％(45／55例),两组比较差异无显著性,治疗1年后两组疗效均有下降,治疗组为78．18％(43／55例),对照组为60．00％(33／55例),治疗组优于对照组(P<0．05),治疗2年后治疗组为87．27％(48／55例),对照组为72．73％(40／55例),两组比较差异无显著性。治疗2年期间感染率和抗生素使用率治疗组分别为23．6％(13／55例)、55．0％(11／20次),对照组分别为50．9％(28／55例)、100％(45／45次),治疗组均明显低于对照组(P<0．01)。结论从肺论治能够降低SLE感染率及抗生素的使用率。

Objective To observe the effect of TCM treatment beginning with Fei in reducing the incidence of complicated infection and the antibiotic utilization rate in patients with systemic lupus erythematosus （SLE）. Methods One hundred and ten SLE patients were randomly assigned to 2 groups equally, the control group treated with the conventional Western medicinal treatment and the treated group treated with the same conventional treatment and SLE Ⅰ formula （in active stage） or SLE Ⅱ formula （in silent period） additionally. Results After 3-month and 6-month treatment, the total effective rate was 83.64 %, 87.27 % in the treated group, and 78.18 %, 81.82 % in the control group respectively, showing insignificant difference between the two groups. It lowered in both groups after 1-year treatment, however, which in the treated group （78.18 % ） was higher than that in the control group （60.00 %, P 〈 0.05）. But the difference became insignificant again after 2-year treatment, it being 87.27% in the treated group and 72.73% in the control group. The incidence of complicated in- fection and antibiotic utilization rate in the 2-year treatment was 23.6 %, 55.0 % respectively in the treated group, markedly lower than those （50.9 % and 100 % ） in the control group respectively （P 〈 0.01 ）. Conclusion TCM treatment beginning with Fei could decrease the incidence of complicated infection and the antibiotic utilization rate in SLE patients.